CN111821098A - Lacrimal passage cannula - Google Patents
Lacrimal passage cannula Download PDFInfo
- Publication number
- CN111821098A CN111821098A CN202010843620.7A CN202010843620A CN111821098A CN 111821098 A CN111821098 A CN 111821098A CN 202010843620 A CN202010843620 A CN 202010843620A CN 111821098 A CN111821098 A CN 111821098A
- Authority
- CN
- China
- Prior art keywords
- lacrimal
- medicine
- cannula
- release layer
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims abstract description 45
- 238000013268 sustained release Methods 0.000 claims abstract description 27
- 239000012730 sustained-release form Substances 0.000 claims abstract description 27
- 238000000465 moulding Methods 0.000 claims abstract description 8
- 230000008961 swelling Effects 0.000 claims abstract description 4
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 239000000017 hydrogel Substances 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 description 13
- 210000003128 head Anatomy 0.000 description 12
- 238000002627 tracheal intubation Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004083 nasolacrimal duct Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010053990 Dacryostenosis acquired Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000083513 Punctum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000000617 lacrimal duct obstruction Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
Abstract
The invention is applicable to the technical field of medical equipment, and provides a lacrimal duct cannula, which comprises: the framework is used for molding drainage; and the sustained-release layer is combined and fixed with the framework in a swelling mode, contains the medicine inside and is used for entering the lacrimal passage and performing sustained-release medicine treatment. The slow release layer can slowly release the medicine after absorbing water in the lacrimal passage to treat the lacrimal passage, the medicine is slowly released through the slow release effect of the slow release layer, the treatment can be continuously carried out, the treatment effect is improved, the medicine is slowly released, the lacrimal passage damage caused by overlarge medicine effect is avoided, and the safety of the medicine treatment is improved.
Description
Technical Field
The invention belongs to the technical field of medical equipment, and particularly relates to a lacrimal duct cannula.
Background
The lacrimal duct obstruction is a common disease and frequently encountered disease in ophthalmology, the prior artificial lacrimal duct is commonly used for treating, two kinds of artificial lacrimal ducts which are used at home and abroad at present are mainly used, one is a thick duct which is specially used for treating the obstruction of the nasolacrimal duct, the other is a thin duct which is specially used for treating the obstruction of the lacrimal duct, and the related reports of complications in the treatment process of the lacrimal duct catheterization in recent years show that the fibrin adhesion obstruction in the lacrimal duct caused by infection and chronic inflammation due to the long-time arrangement of material pipes such as silica gel and the like, even the adhesion of the lacrimal duct is caused by the formation of fixed scars, the blockage of the lacrimal duct of a serious patient occurs, surrounding tissues and organs are stimulated, the original disease is not well recovered, the persistence is not achieved, and the life quality of the patient is seriously affected.
Disclosure of Invention
The embodiment of the invention aims to provide a lacrimal duct cannula, aiming at solving the problems of susceptibility and chronic inflammation.
Embodiments of the present invention are achieved by a lacrimal cannula, comprising:
the framework is used for molding drainage;
and the sustained-release layer is combined and fixed with the framework in a swelling mode, contains the medicine inside and is used for entering the lacrimal passage and performing sustained-release medicine treatment.
In the embodiment of the invention, when the lacrimal passage intubation is used, firstly, the lacrimal passage is fully expanded, the lacrimal canaliculus and the narrow part of the nasolacrimal duct are probed by using a lacrimal passage probe, the lacrimal passage is washed, the medicine-carrying lacrimal passage intubation is taken out for standby, the inserted steel wire core is matched with the lacrimal passage intubation and inserted into the lacrimal passage, the metal wire core is fed according to the probing method, the lacrimal passage intubation is inserted, the catheter can be knotted or fixed, the sustained-release layer absorbs water in the lacrimal passage and carries out sustained-release medicine to treat the lacrimal passage, and the medicine is slowly released through the sustained-release effect of the sustained-release layer, so that the treatment effect is improved, the medicine is slowly released, the lacrimal passage injury caused by overlarge medicine effect is avoided, the safety of the medicine treatment is improved, the sustained-release layer has hydrophilic performance after water absorption, and the use comfort level of the lacrimal passage intubation is improved.
As a preferred embodiment of the invention, the skeleton is of a hollow tubular structure, so that the sustained-release layer can be supported, the supporting area is increased, the supporting strength is increased, meanwhile, the contact area of the sustained-release layer and the lacrimal duct is increased, and the use discomfort caused by scratching is avoided.
As a preferred embodiment of the invention, the framework is made of silica gel, so that the framework has enough supporting capacity, corresponding flexibility, no toxicity, no smell and stable chemical property.
As a preferred embodiment of the invention, the slow release layer is made of hydrogel materials and is provided with a part of hydrophobic groups and hydrophilic residues, and the hydrophilic residues are combined with water molecules to form a high-molecular network system which is soft in property, can keep a certain shape and can absorb a large amount of water.
As a preferred embodiment of the invention, the hydrogel is made of sodium alginate, the sodium alginate has strong hydrophilicity, can be slowly dissolved in the lacrimal passage for drug slow release to form a very viscous uniform solution, and has the characteristics of softness, uniformity and the like; the pH value is 7, the product is neutral and can be adjusted to be high in safety; can be made into tough fiber or film with anti-cracking effect; small adhesion, high flexibility, easy molding, low cost and easy acquisition.
As a preferred embodiment of the invention, the length of the framework is 150-250mm, so that the framework can be suitable for various people.
As a preferred embodiment of the present invention, the length of the skeleton is 200mm, thereby facilitating sufficient insertion into the lacrimal passage and treatment and fixation.
As another preferred embodiment of the invention, the outer diameter of the skeleton is about 0.3-1.2mm, and the main indication is blockage near the lacrimal canaliculus, which is convenient for inserting a lacrimal duct cannula into the lacrimal duct, and is convenient for dredging the lacrimal duct and fully expanding the lacrimal duct.
As another preferred embodiment of the invention, the insertion end of the framework is provided with an expansion piece for expanding the lacrimal passage, and the expansion piece is of a non-sealing structure and is communicated with the framework to form a drainage channel; the expansion piece is inserted into the inner part of the lacrimal passage, so that the lacrimal passage can be conveniently expanded, and the insertion tube can conveniently enter.
As another preferred embodiment of the invention, the extension piece can be one of a hollow annular-structure annular head, a hammer-shaped structure or an ellipsoidal-structure capsule head, so that the extension piece is attached to the lacrimal sac part to the maximum extent, and the molding effect is greatly improved.
As another preferred embodiment of the invention, when the expansion piece is in a hammer-shaped structure, the length of the head part is about 5-6 mm; the length of the body part is about 50mm, and the width of the head part is 4-7 mm; the body width is about 0.5-5 mm. The body width is 0.5-1mm, and is suitable for children, and the body width is about 4, and is suitable for adults.
According to the lacrimal duct cannula provided by the embodiment of the invention, the slow release layer absorbs water in the lacrimal duct and slowly releases the medicine to treat the lacrimal duct, the medicine is slowly released through the slow release effect of the slow release layer, the treatment can be continuously carried out, the treatment effect is improved, the medicine is slowly released, the lacrimal duct damage caused by overlarge medicine effect is avoided, and the safety of the medicine quality is improved. According to the disease of the patient, the concentration and the release time of the medicine are regulated and controlled, the targeted treatment can be carried out, the medicine damage is avoided, and the treatment effect is improved. The expansion piece has a certain matching degree in anatomical shape, has certain rigidity and plasticity, can remold and keep smooth to the maximum extent, and cannot damage the original physiological pipeline structure.
Drawings
Fig. 1 is a schematic structural view of a lacrimal cannula according to an embodiment of the present invention;
fig. 2 is a schematic structural view of a lacrimal cannula with an annular head according to an embodiment of the present invention;
fig. 3 is a schematic structural view of a lacrimal cannula with a capsule-shaped head according to an embodiment of the present invention;
in the drawings: the slow-release capsule comprises a framework 1, a slow-release layer 2, an annular head 3 and a capsule head 4.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Specific implementations of the present invention are described in detail below with reference to specific embodiments.
As shown in fig. 1, a structural diagram of a lacrimal cannula provided in an embodiment of the present invention includes:
the framework 1 is used for molding drainage;
and the sustained-release layer 2 is combined and fixed with the framework 1 in a swelling mode, contains the medicine inside and is used for entering the lacrimal passage and performing sustained-release medicine treatment.
In the embodiment of the invention, when in use, firstly, the lacrimal punctum is fully expanded, the lacrimal canaliculus and the narrow part of the nasolacrimal duct are probed by using a lacrimal probe, the lacrimal duct is washed, the medicine-carrying lacrimal duct cannula is taken out for standby, the inserted steel wire core is matched with the lacrimal duct cannula to be inserted into the lacrimal duct, the inserted steel wire core is fed according to the probing method, the metal wire core is drawn out, the lacrimal duct cannula is inserted, and then the catheter can be knotted or fixed, the sustained-release layer 2 absorbs water in the lacrimal duct and sustainedly releases the medicine to treat the lacrimal duct, the medicine is slowly released through the sustained-release action of the sustained-release layer 2, the treatment can be continuously carried out, the treatment effect is improved, the medicine is slowly released, the lacrimal duct damage caused by overlarge medicine effect is avoided, the safety of the medicine treatment is improved, the sustained-release layer 2 has hydrophilic performance after water absorption, and the.
In one embodiment of the present invention, the matrix 1 has a supporting function, so as to ensure the formation of the sustained-release layer 2, and the sustained-release layer 2 is internally wrapped with the drug, so as to facilitate the storage of the drug or directly mixed with the drug, and swells to release the drug after absorbing water. The medicament may be an anti-inflammatory, an antibacterial such as an antibiotic, etc., although other therapeutic agents are not excluded.
As a preferred embodiment of the invention, the framework 1 is a hollow tubular structure, so that the sustained-release layer 2 can be supported, the supporting area is increased, the supporting strength is increased, meanwhile, the contact area of the sustained-release layer 2 and the lacrimal duct is increased, and the use discomfort caused by scratching is avoided. The framework 1 is made of silica gel, so that the framework 1 has enough supporting capacity and corresponding flexibility, is non-toxic and odorless and has stable chemical properties.
As a preferred embodiment of the invention, the slow release layer 2 is made of hydrogel material and has a part of hydrophobic groups and hydrophilic residues, and the hydrophilic residues are combined with water molecules to form a high molecular network system, so that the slow release layer is soft in property, can keep a certain shape and can absorb a large amount of water.
As a preferred embodiment of the invention, the hydrogel is made of sodium alginate, the sodium alginate has strong hydrophilicity, can be slowly dissolved in the lacrimal passage for drug slow release to form a very viscous uniform solution, and has the characteristics of softness, uniformity and the like; the pH value is 7, the product is neutral and can be adjusted to be high in safety; can be made into tough fiber or film with anti-cracking effect; small adhesion, high flexibility, easy molding, low cost and easy acquisition.
As a preferred embodiment of the present invention, the length of the frame 1 is 150-250mm, so that the frame can be suitable for various people.
As a preferred embodiment of the present invention, the length of the frame 1 is 200mm, thereby facilitating sufficient insertion into the lacrimal passage and treatment and fixation.
As another preferred embodiment of the invention, the outer diameter of the framework 1 is about 0.3-1.2mm, and the main indication is blockage near the lacrimal canaliculus, which is convenient for inserting a lacrimal duct cannula into the lacrimal duct, and is convenient for dredging the lacrimal duct and fully expanding the lacrimal duct.
As shown in fig. 2-3, as another preferred embodiment of the present invention, an expansion piece for expanding lacrimal passage is provided at the insertion end of the skeleton 1, the expansion piece is a non-sealing structure and is communicated with the skeleton 1 to form a drainage channel; the expansion piece is inserted into the inner part of the lacrimal passage, so that the lacrimal passage can be conveniently expanded, and the insertion tube can conveniently enter.
As another preferred embodiment of the invention, the extension piece can be one of a hollow annular-structure annular head 3, a hammer-shaped structure or an ellipsoidal-structure capsule head 4, so that the extension piece is close to the lacrimal sac part to the maximum extent, and the molding effect is greatly improved.
As another preferred embodiment of the invention, when the expansion piece is in a hammer-shaped structure, the length of the head part is about 5-6 mm; the length of the body part is about 50mm, and the width of the head part is 4-7 mm; the body width is about 0.5-5 mm. The body width is 0.5-1mm, and is suitable for children, and the body width is about 4, and is suitable for adults.
The lacrimal duct cannula is inserted into the lacrimal duct, the sustained release layer 2 absorbs water in the lacrimal duct and releases the drug slowly to treat the lacrimal duct, the drug is released slowly through the sustained release effect of the sustained release layer 2, the treatment can be carried out continuously, the treatment effect is improved, the drug is released slowly, the lacrimal duct damage caused by overlarge drug effect is avoided, and the safety of the drug quality is improved. The concentration and the release time of the drug can be regulated and controlled as required, the drug can be completely released in about 1-2 months on average, the treatment effect is obvious, the drug sustained-release layer 2 has hydrophilic performance after absorbing water, and the use comfort of the lacrimal duct cannula is improved. The expansion piece has a certain matching degree in anatomical shape, has certain rigidity and plasticity, can remold and keep smooth to the maximum extent, and cannot damage the original physiological pipeline structure.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (10)
1. A lacrimal cannula, comprising:
the framework is used for molding drainage;
and the sustained-release layer is combined and fixed with the framework in a swelling mode, contains the medicine inside and is used for entering the lacrimal passage and performing sustained-release medicine treatment.
2. The lacrimal cannula of claim 1, wherein the frame is a hollow tubular structure.
3. The lacrimal cannula of claim 1, wherein the frame is made of silicone.
4. The lacrimal cannula of claim 1, wherein the slow release layer is made of a hydrogel material.
5. The lacrimal cannula of claim 4, wherein the hydrogel is made of sodium alginate.
6. The lacrimal cannula of claim 1, wherein the length of the frame is 150-250 mm.
7. The lacrimal cannula of claim 6, wherein the length of the skeleton is 200 mm.
8. The lacrimal cannula of claim 1, wherein the outer diameter of the frame is 0.3-1.2 mm.
9. The lacrimal cannula according to any of claims 1-8, wherein the insertion end of the frame is provided with an expansion member for expanding the lacrimal passage, the expansion member being a non-sealing structure and communicating with the frame to form a drainage channel.
10. The lacrimal cannula of claim 9, wherein the augment is one of a hollow ring structure, a hammer structure, or an ellipsoid structure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010843620.7A CN111821098A (en) | 2020-08-20 | 2020-08-20 | Lacrimal passage cannula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010843620.7A CN111821098A (en) | 2020-08-20 | 2020-08-20 | Lacrimal passage cannula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111821098A true CN111821098A (en) | 2020-10-27 |
Family
ID=72918230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010843620.7A Pending CN111821098A (en) | 2020-08-20 | 2020-08-20 | Lacrimal passage cannula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111821098A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652511A (en) * | 2022-05-19 | 2022-06-24 | 茂名市人民医院 | Medicine-carrying degradable lacrimal passage suppository |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2109832U (en) * | 1991-06-19 | 1992-07-15 | 傅靖 | Dilate washing conduit for lacrimal duct |
| CN2251369Y (en) * | 1995-08-04 | 1997-04-09 | 李绍君 | Casing for curing lacrimal passage obstruction |
| CN2489747Y (en) * | 2001-07-18 | 2002-05-08 | 肖满意 | Bud-shape drain type artificial lacrimal duct |
| US20090264861A1 (en) * | 2008-02-18 | 2009-10-22 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
| CN203138818U (en) * | 2013-01-11 | 2013-08-21 | 攀枝花钢铁有限责任公司职工总医院 | Lacrimal passage cannula |
| CN205459331U (en) * | 2016-02-19 | 2016-08-17 | 重庆医科大学附属儿童医院 | Children's tear way pipe |
| CN108395507A (en) * | 2018-03-08 | 2018-08-14 | 广州锐澄医疗技术有限公司 | A kind of preparation method of the lacrimal bolt with drug slow release function |
| CN109288622A (en) * | 2018-11-02 | 2019-02-01 | 广州悦清再生医学科技有限公司 | A kind of conduit with tissue protective outer embrane, preparation method and application |
-
2020
- 2020-08-20 CN CN202010843620.7A patent/CN111821098A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2109832U (en) * | 1991-06-19 | 1992-07-15 | 傅靖 | Dilate washing conduit for lacrimal duct |
| CN2251369Y (en) * | 1995-08-04 | 1997-04-09 | 李绍君 | Casing for curing lacrimal passage obstruction |
| CN2489747Y (en) * | 2001-07-18 | 2002-05-08 | 肖满意 | Bud-shape drain type artificial lacrimal duct |
| US20090264861A1 (en) * | 2008-02-18 | 2009-10-22 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
| CN203138818U (en) * | 2013-01-11 | 2013-08-21 | 攀枝花钢铁有限责任公司职工总医院 | Lacrimal passage cannula |
| CN205459331U (en) * | 2016-02-19 | 2016-08-17 | 重庆医科大学附属儿童医院 | Children's tear way pipe |
| CN108395507A (en) * | 2018-03-08 | 2018-08-14 | 广州锐澄医疗技术有限公司 | A kind of preparation method of the lacrimal bolt with drug slow release function |
| CN109288622A (en) * | 2018-11-02 | 2019-02-01 | 广州悦清再生医学科技有限公司 | A kind of conduit with tissue protective outer embrane, preparation method and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652511A (en) * | 2022-05-19 | 2022-06-24 | 茂名市人民医院 | Medicine-carrying degradable lacrimal passage suppository |
| CN114652511B (en) * | 2022-05-19 | 2022-09-02 | 茂名市人民医院 | Medicine-carrying degradable lacrimal passage suppository |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6312258B2 (en) | Device for transanal drainage of excreta from a patient's rectum and / or transanal application of inflowing fluid through a catheter-like element | |
| JP3748569B2 (en) | Therapeutic device for selective cell reduction treatment of disorders within natural lumens or passages in the human or animal body | |
| JPH11507353A (en) | Methods and compositions for chemically causing necrosis in the uterus | |
| US20090186061A1 (en) | Composition Comprising Polymeric, Water-Insoluble, Anionic Particles, Processes and Uses | |
| CN103111010A (en) | Double-cavity sacculus tube and application thereof | |
| US6768040B1 (en) | Wound dressing for treating injury to nasal passages | |
| CN111821098A (en) | Lacrimal passage cannula | |
| CN210472770U (en) | Oviduct radiography and liquid-flowing catheter | |
| KR20020094074A (en) | Implantation tube in the body | |
| US20200368008A1 (en) | Urological Stent | |
| CN108578879B (en) | Special catheter for children's reducing saccule dilating vascular stent | |
| CN215915242U (en) | Eustachian tube expansion and transmission device with full-degradable drug stent | |
| CN211023323U (en) | Completely absorbable nasolacrimal duct stent and conveying system thereof | |
| WO2009004626A2 (en) | Articles for maintaining sterility of a bodily orifice or a wound site | |
| EP2742966A1 (en) | Application of water-absorption material in medical cavity channel expander | |
| CN203138818U (en) | Lacrimal passage cannula | |
| CN210673411U (en) | Ovary injection device and device for diagnosing, preventing or treating ovarian diseases | |
| CN106924865B (en) | Urethral dilator | |
| CN201564941U (en) | Supporting drainage tube after urethral reconstruction operation | |
| CN111096831A (en) | Anti-infection absorbable urethral stent used after hypospadias operation | |
| CN217772398U (en) | Cervical dilation instrument | |
| KR200471253Y1 (en) | Hyun's ring | |
| CN213075860U (en) | Instrument for cervical dilatation | |
| WO2020052136A1 (en) | Degradable foldable biological amniotic membrane composite repair stent | |
| KR20120128911A (en) | Hyun's ring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201027 |
|
| RJ01 | Rejection of invention patent application after publication |